CORPORATE CONTRIBUTIONS IN EXCESS OF $50 MIL. TO NIH-FUNDED
CORPORATE CONTRIBUTIONS IN EXCESS OF $50 MIL. TO NIH-FUNDED institutions should trigger a public disclosure requirement, a 12- member panel convened by the National Institutes of Health recommended at a Jan. 25-26 forum in Bethesda, Md. "NIH may very well want to know that a particular grantee has in place something of significant scope and size that could really affect the operations there, even though NIH might conclude after reviewing it that they're perfectly satisfied...that ultimately it raises no Bayh-Dole [Act] concern," commented panelist Jose Trias, Howard Hughes Medical Institute.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth